David Jilich

Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance

Enhancing extracellular vesicle cargo loading and functional delivery by engineering protein-lipid interactions

HIV

A central hydrophobic E1 region controls the pH range of hepatitis C virus membrane fusion and susceptibility to fusion inhibitors

Lymphogranuloma Venereum 2015: Clinical Presentation, Diagnosis, and Treatment: Table 1.

Switching to Tenofovir Alafenamide, Coformulated With Elvitegravir, Cobicistat, and Emtricitabine, in HIV-Infected Patients With Renal Impairment

Exosome-mediated stable epigenetic repression of HIV-1

EASL 2017 Clinical Practice Guidelines on the management of hepatitis B virus infection

Sexually Transmitted Infections Treatment Guidelines, 2021

A Randomized, Open-Label Trial to Evaluate Switching to Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide Plus Darunavir in Treatment-Experienced HIV-1-Infected Adults

Effect of immediate initiation of antiretroviral therapy on risk of severe bacterial infections in HIV-positive people with CD4 cell counts of more than 500 cells per μL: secondary outcome results from a randomised controlled trial

Development of 5‘ LTR DNA methylation of latent HIV-1 provirus in cell line models and in long-term-infected individuals

[Guidelines for caring for HIV-infected adults and post-exposure prophylaxis of HIV infection].

First detection of Chlamydia trachomatis LGV biovar in the Czech Republic, 2010–2011